The thiopurine methyltransferase genetic polymorphism is associated with thioguanine-related veno-occlusive disease of the liver in children with acute lymphoblastic leukemia

Clinical Pharmacology and Therapeutics

Volumn 80, Issue 4, 2006, Pages 375-383

  Lennard, Lynne ^a   Richards, Sue ^a   Cartwright, Cher S ^a   Mitchell, Chris ^a   Lilleyman, John S ^a   Vora, Ajay ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MERCAPTOPURINE; THIOPURINE METHYLTRANSFERASE; TIOGUANINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CHILD; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DNA POLYMORPHISM; ENZYME ACTIVITY; ERYTHROCYTE; FEMALE; FOLLOW UP; HUMAN; LIVER TOXICITY; LIVER VEIN OBSTRUCTION; MAJOR CLINICAL STUDY; MALE; PORTAL HYPERTENSION; PRIORITY JOURNAL; QUESTIONNAIRE; SPLENOMEGALY; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; THROMBOCYTOPENIA;

6-MERCAPTOPURINE; ADOLESCENT; ANTIMETABOLITES, ANTINEOPLASTIC; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; HYPERTENSION, PORTAL; INFANT; INFANT, NEWBORN; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; MALE; METHYLTRANSFERASES; POLYMORPHISM, GENETIC; SPLENOMEGALY; THIOGUANINE;

EID: 33749255187     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2006.07.002     Document Type: Article

References (44)

1. Elion G., Burgi E., and Hitchings G. Studies on condensed pyrimidine systems. IX. The synthesis of some 6-substituted purines. J Am Chem Soc 74 (1952) 411-414
2. Burchenal J.H., Murphy M., Ellison R., Sykes M.P., Tan T.C., Leone L.A., et al. Clinical evaluation of a new antimetabolite, 6-mercaptopurine, in the treatment of leukemia and allied diseases. Blood 8 (1953) 965-999
3. Murphy M.L., Tan T.C., Ellison R.R., Karnofsky D.A., and Burchenal J.H. Clinical evaluation of chloropurine and thioguanine. Proc Am Assoc Cancer Res 2 (1955) 36-39
4. Brox L.W., Birkett L., and Belch A. Clinical pharmacology of oral thioguanine in acute myelogenous leukemia. Cancer Chemother Pharmacol 6 (1981) 35-38
5. Lennard L., Davies H.A., and Lilleyman J.S. Is 6-thioguanine more appropriate than 6-mercaptopurine for children with acute lymphoblastic leukaemia?. Br J Cancer 68 (1993) 186-190
6. Adamson P.C., Poplack D.G., and Balis F.M. The cytotoxicity of thioguanine vs mercaptopurine in acute lymphoblastic leukemia. Leuk Res 18 (1994) 805-810
7. Evans W.E., and Relling M.V. Mercaptopurine vs thioguanine for the treatment of acute lymphoblastic leukemia. Leuk Res 18 (1994) 811-814
8. Zimm S., Collins J.M., O'Niell D., Chabner B.A., and Poplack D.G. Inhibition of first-pass metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinol. Clin Pharmacol Ther 34 (1983) 810-817
9. Weinshilboum R. Thiopurine pharmacogenetics: clinical and molecular studies of thiopurine methyltransferase. Drug Metab Dispos 29 (2001) 601-605
10. Tiede I., Fritz G., Strand S., Poppe D., Dvorsky R., Strand D., et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 111 (2003) 1133-1145
11. Weinshilboum R.M., and Sladek S.L. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 32 (1980) 651-662
12. McLeod H.L., Relling M.V., Liu Q., Pui C.-H., and Evans W.E. Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia. Blood 7 (1995) 1897-1902
13. Lennard L., Van Loon J.A., and Weinshilboum R.M. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 46 (1989) 149-154
14. Lennard L., Gibson B.E.S., Nicole T., and Lilleyman J.S. Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia. Arch Dis Child 69 (1993) 577-579
15. Relling M.V., Hancock M.L., Rivera G.K., Sandlund J.T., Ribeiro R.C., Krynetski E.Y., et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 91 (1999) 2001-2008
16. Lennard L., Lilleyman J.S., Van Loon J.A., and Weinshilboum R.M. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 336 (1990) 225-229
17. Relling M.V., Hancock M.L., Boyett J.M., Pui C.-H., and Evans W.E. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood 93 (1999) 2817-2823
18. Imperial Cancer Research Fund. MRC ALL97. Available from: URL:http://www.icnet.uk/trials/children/mrcall97.html. Accessed Sept 1, 2006.
19. Mitchell C.D., Richards S.M., Lilleyman J., Vora A., and Eden O.B. Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomised trial. Br J Haematol 129 (2005) 734-745
20. Hann I., Vora A., Richards S., Hill F., Gibson B., Lilleyman J., et al. Benefit of intensified treatment for all children with acute lymphoblastic leukaemia: results from MRC UKALL XI and MRC ALL97 randomised trials. Leukaemia 14 (2000) 356-363
21. Schrappe M., Camitta B., Pui C.-H., Eden T., Gaynon P., Gustafsson G., et al. Long-term results of large prospective trials in childhood acute lymphoblastic leukemia. Leukemia 14 (2000) 2193-2194
22. Lennard L., and Singleton H.J. High performance liquid chromatographic assay of human red blood cell thiopurine methyltransferase activity. J Chromatogr B Biomed Appl 661 (1994) 25-33
23. Otterness D., Szumlanski C., Lennard L., Klemetsdal B., Aarbakke J., Park-Hah J.O., et al. Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin Pharmacol Ther 62 (1997) 60-73
24. Lennard L., and Singleton H. High-performance liquid chromatographic assay of the methyl and nucleotide metabolites of 6-mercaptopurine: quantitation of red blood cell 6-thioguanine nucleotide, 6-thioinosinic acid and 6-methylmercaptopurine metabolites in a single sample. J Chromatogr 583 (1992) 83-90
25. McLeod H.L., Pritchard S.C., Githhang J., Indalo A., Ameyaw M.-M., Powrie R.H., et al. Ethnic differences in thiopurine methyltransferase pharmacogenetics: evidence for allele specificity in Caucasian and Kenyan individuals. Pharmacogenetics 9 (1999) 773-776
26. Kham S.K.Y., Tan P.L., Tay A.H.N., Heng C.K., Yeoh A.E.J., and Quah T.-C. Thiopurine methyltransferase polymorphisms in a multiracial Asian population and children with acute lymphoblastic leukemia. J Pediatr Hematol Oncol 24 (2002) 353-359
27. Yates C.R., Krynetski E.Y., Loennechen T., Fessing M.Y., Tai H.-L., Pui C.-H., et al. Molecular diagnosis of thiopurine S-methyltrasferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 126 (1997) 608-614
28. Schaeffeler E., Fisher C., Brockmeier D., Wernet D., Moerike K., Eichelbaum M., et al. Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics 14 (2004) 407-417
29. Lennard L., Chew T.S., and Lilleyman J.S. Human thiopurine methyltransferase activity varies with red blood cell age. Br J Clin Pharmacol 52 (2001) 539-546
30. Lennard L., Hale J.P., and Lilleyman J.S. Red blood cell hypoxanthine phosphoribosyltransferase activity measured using 6-mercaptopurine as a substrate: a population study in children with acute lymphoblastic leukaemia. Br J Clin Pharmacol 36 (1993) 277-284
31. Evans W.E. Pharmacogenetics of thiopurine S-methyltransferase and thiopurine therapy. Ther Drug Monit 26 (2004) 186-191
32. Zackheim H.S., Glogau R.G., Fisher D.A., and Maibach H.I. 6-Thioguanine treatment of psoriasis: experience in 81 patients. J Am Acad Dermatol 30 (1994) 452-458
33. Mason C., and Frueger G.G. Thioguanine for refractory psoriasis: a 4-year experience. J Am Acad Dermatol 44 (2001) 67-72
34. Murphy F.P., Coven T.R., Burack L.H., Gilleaudeau P., Cardinale I., Auerbach R., et al. Clinical clearing of psoriasis by 6-thioguanine correlates with cutaneous T-cell depletion and apoptosis. Arch Dermatol 135 (1999) 1495-1502
35. Kao N.L., and Rosenblate H.J. 6-Thioguanine therapy for psoriasis causing toxic hepatic venoocclusive disease. J Am Acad Dermatol 28 (1993) 1017-1018
36. Shepherd P.C.A., Fooks J., Gray R., and Allan N.C. Thioguanine used in the maintenance therapy of chronic myeloid leukaemia causes non-cirrhotic portal hypertension. Br J Haematol 79 (1991) 185-192
37. Schmeigelow K., and Pulczynska M. Prognostic significance of hepatotoxicity during maintenance chemotherapy for childhood acute lymphoblastic leukaemia. Br J Cancer 61 (1990) 767-772
38. Holtmann M., Schreiner O., Kohler H., Denzer U., Neurath M., Galle P.R., et al. Veno-occlusive disease in Crohn's disease treated with azathioprine. Dig Dis Sci 48 (2003) 1503-1505
39. Azoulay D., Castaing D., Lemoine A., Samuel D., Majno, Reynes M., et al. Successful treatment of severe azathioprine-induced hepatic veno-occlusive disease in a kidney-transplanted patient with transjugular intrahepatic portosystemic shunt. Clin Nephrol 50 (1998) 118-120
40. Laidlaw S.T., Reilly J.T., and Suvarna S.K. Fatal hepatotoxicity associated with 6-mercaptopurine therapy. Postgrad Med J 71 (1995) 639
41. Stoneham S., Lennard L., Coen P., Lilleyman J., and Saha V. Veno-occlusive disease in patients receiving thiopurines during maintenance therapy for childhood acute lymphoblastic leukaemia. Br J Haematol 122 (2003) 1-3
42. Piel B., Vaidya S., Lancaster D., Taj M., and Pritchard-Jones K. Chronic hepatotoxicity following 6-thioguanine therapy for childhood acute lymphoblastic leukaemia. Br J Haematol 125 (2004) 410-411
43. Broxson E.H., Dole M., Wong R., Laya B.F., and Stork L. Portal hypertension develops in a subset of children with standard risk acute lymphoblastic leukemia treated with oral 6-thioguanine during maintenance therapy. Pediatr Blood Cancer 44 (2005) 226-231
44. Harms D.O., Gobel U., Spaar H.J., Grauber U.B., Jorch N., Gutjahr P., et al., COALL Study Group. Thioguanine offers no advantage over mercaptopurine in maintenance treatment of childhood ALL: results of the randomized trial COALL-92. Blood 102 (2003) 2736-2740